Herbert Lyerly
Overview:
Positions:
George Barth Geller Distinguished Professor of Immunology
Surgery, Surgical Sciences
School of Medicine
Professor of Surgery
Surgery, Surgical Sciences
School of Medicine
Professor in Immunology
Integrative Immunobiology
School of Medicine
Professor of Pathology
Pathology
School of Medicine
Affiliate, Duke Global Health Institute
Duke Global Health Institute
Institutes and Provost's Academic Units
Core Faculty Member, Duke-Margolis Center for Health Policy
Duke - Margolis Center For Health Policy
Institutes and Provost's Academic Units
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Affiliate of the Duke Regeneration Center
Regeneration Next Initiative
School of Medicine
Education:
M.D. 1983
University of California - Los Angeles
Grants:
A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes
Administered By
Basic Science Departments
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
Administered By
Medicine, Gastroenterology
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date
A Molecular Framework for Understanding DCIS
Administered By
Surgery, Surgical Sciences
Awarded By
Department of Defense
Role
Principal Investigator
Start Date
End Date
Advancing Immunology in Dogs with Naturally-occurring Invasive Bladder Cancer, a Relevant Model to Improve Immunotherapy Across Molecular Cancer Subtypes in Humans
Awarded By
Purdue University
Role
Principal Investigator
Start Date
End Date
Administrative Supplement for Recruitment of New Faculty
Administered By
Duke Cancer Institute
Awarded By
National Cancer Institute
Role
Principal Investigator
Start Date
End Date
Publications:
Supplementary Figure 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>Analysis of HER2BOW tumors</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Supplementary Figure 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526399.
URI
https://scholars.duke.edu/individual/pub1571968
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526399
Supplementary Methods from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils
<jats:p><p>Detailed and supplementary methods</p></jats:p>
Authors
Trotter, TN; Shuptrine, CW; Tsao, L-C; Marek, RD; Acharya, C; Wei, J-P; Yang, X-Y; Lei, G; Wang, T; Lyerly, HK; Hartman, ZC
MLA Citation
Trotter, Timothy N., et al. Supplementary Methods from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils. 31 Mar. 2023. Crossref, doi:10.1158/0008-5472.22423281.
URI
https://scholars.duke.edu/individual/pub1571704
Source
crossref
Published Date
DOI
10.1158/0008-5472.22423281
Table S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
<jats:p><p>CYTOF Panel</p></jats:p>
Authors
Crosby, EJ; Gwin, W; Blackwell, K; Marcom, PK; Chang, S; Maecker, HT; Broadwater, G; Hyslop, T; Kim, S; Rogatko, A; Lubkov, V; Snyder, JC; Osada, T; Hobeika, AC; Morse, MA; Lyerly, HK; Hartman, ZC
MLA Citation
Crosby, Erika J., et al. Table S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22472850.v1.
URI
https://scholars.duke.edu/individual/pub1571742
Source
crossref
Published Date
DOI
10.1158/1078-0432.22472850.v1
Self-replicating messenger RNA based cancer immunotherapy.
Authors
MLA Citation
Lyerly, Herbert Kim. “Self-replicating messenger RNA based cancer immunotherapy.” Cancer Gene Ther, May 2023, pp. 1–2. Pubmed, doi:10.1038/s41417-023-00619-w.
URI
https://scholars.duke.edu/individual/pub1575262
PMID
37147521
Source
pubmed
Published In
Cancer Gene Ther
Published Date
Start Page
1
End Page
2
DOI
10.1038/s41417-023-00619-w
Supplementary Figure 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>MaXFISH coregistry of sequenced tumors</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Supplementary Figure 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526393.v1.
URI
https://scholars.duke.edu/individual/pub1571969
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526393.v1
George Barth Geller Distinguished Professor of Immunology
Contact:
203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710
Box 2606 Med Ctr, Durham, NC 27710